跳至主要内容
临床试验/NCT00579709
NCT00579709已完成1 期

Thymus Transplantation With Immunosuppression, #884

Sumitomo Pharma Switzerland GmbH2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2002年7月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
15
试验地点
2
主要终点
Safety & tolerability of Thymoglobulin and cyclosporine followed by thymus transplantation: Survival at 1 year post-transplantation.

研究概览

简要总结

The research purpose is to determine if thymus transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly. The research includes studies to evaluate whether thymus transplantation results in complete DiGeorge anomaly subjects developing a normal immune system.

详细描述

DiGeorge anomaly is a complex of cardiac defects, parathyroid deficiency, and thymus absence, resulting in profound T-cell deficiency. There is a spectrum of disease in DiGeorge anomaly with respect to all three defects. For complete DiGeorge anomaly subjects with severe T cell defect, the PI had shown that thymus transplantation is safe and efficacious without pretransplantation immunosuppression and with pretransplantation Thymoglobulin and cyclosporine.

Some DiGeorge patients have very poor T cell function and are at risk of death from infection or other immune problems; however, these patients have enough T cell function to reject grafts. This protocol was designed for these patients. Atypical phenotype and some typical phenotype DiGeorge subjects were included in this protocol.

Atypical complete DiGeorge anomaly patients have rash, lymphadenopathy, and oligoclonal T cell proliferations. The T cells have no markers of thymic function (they do not co-express CD45RA and CD62L; they do not contain T cell receptor rearrangement excision circles, TRECs).

Typical complete DiGeorge anomaly patients in this protocol are those whose PHA response >20 fold. Although these patients have very low T cell function, it may be enough to reject a transplant, so Thymoglobulin was used.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Safety & tolerability of Thymoglobulin and cyclosporine followed by thymus transplantation: Survival at 1 year post-transplantation.

时间窗: 1 year post-transplantation

次要结局

  • Allograft biopsy used to evaluate graft rejection(2 to 4 months post-transplant)
  • Use of additional post transplant immunosuppression after that listed in the protocol.(The post thymus transplantation period)
  • CD3 count(10 - 14 months post-transplantation)
  • CD8 count(10-14 months after thymus transplantation)
  • Thymopoiesis(2-4 months after thymus transplantation)
  • CD4 count(10-14 months after thymus transplantation)
  • naive CD4 count(10-14 months after thymus transplantation)
  • naive CD8 count(10-14 months after thymus transplantation)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验